

# Ana Eugenia RodrÃ-iguez-Vicente

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/725472/publications.pdf>

Version: 2024-02-01

31  
papers

587  
citations

687335

13  
h-index

642715

23  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1028  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>TRAF3</i> alterations are frequent in del(11q) chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. <i>American Journal of Hematology</i> , 2022, 97, 903-914.	4.1	3
2	Dissecting the role of <i>TP53</i> alterations in del(11q) chronic lymphocytic leukemia. <i>Clinical and Translational Medicine</i> , 2021, 11, e304.	4.0	7
3	NEMHESYS – European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics. <i>HemaSphere</i> , 2021, 5, e541.	2.7	2
4	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. <i>Cancers</i> , 2021, 13, 1782.	3.7	10
5	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. <i>Diagnostics</i> , 2021, 11, 853.	2.6	15
6	Biological significance of monoallelic and biallelic <i>BIRC3</i> loss in del(11q) chronic lymphocytic leukemia progression. <i>Blood Cancer Journal</i> , 2021, 11, 127.	6.2	12
7	Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag. <i>Platelets</i> , 2020, 31, 993-1000.	2.3	10
8	Chronic lymphocytic leukemia patients with <i>IGH</i> translocations are characterized by a distinct genetic landscape with prognostic implications. <i>International Journal of Cancer</i> , 2020, 147, 2780-2792.	5.1	19
9	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. <i>Leukemia</i> , 2020, 34, 1599-1612.	7.2	21
10	Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 664-671.	2.0	3
11	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 548-555.e4.	0.4	10
12	Clinical and Biological Impact of <i>TP53</i> Alterations in Del(11q) Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 6-7.	1.4	1
13	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. <i>Haematologica</i> , 2020, 106, 87-97.	3.5	43
14	Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. <i>Scientific Reports</i> , 2020, 10, 8394.	3.3	5
15	Biological Impact of Monoallelic and Biallelic <i>BIRC3</i> Loss in Del(11q) Chronic Lymphocytic Leukemia Progression. <i>Blood</i> , 2020, 136, 4-4.	1.4	0
16	DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains. <i>Experimental Hematology</i> , 2019, 72, 9-13.	0.4	9
17	CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. <i>Leukemia</i> , 2019, 33, 518-558.	7.2	15
18	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 633-642.	1.3	8

#	ARTICLE	IF	CITATIONS
19	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	18
20	Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 83.	17.0	38
21	Hyperdiploidy as a rare event that accompanies poor prognosis markers in <scp>CLL</scp>. <i>European Journal of Haematology</i> , 2017, 98, 142-148.	2.2	4
22	Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. <i>Oncotarget</i> , 2017, 8, 71234-71248.	1.8	25
23	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2016, 34, 84-92.	1.7	26
24	MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. <i>Leukemia Research</i> , 2016, 46, 30-36.	0.8	8
25	Pharmacogenetics and pharmacogenomics as tools in cancer therapy. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 25-34.	0.6	23
26	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0143073.	2.5	24
27	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. <i>BMC Cancer</i> , 2015, 15, 238.	2.6	16
28	ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. <i>Haematologica</i> , 2014, 99, 736-742.	3.5	69
29	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. <i>Cancer Genetics</i> , 2013, 206, 49-62.	0.4	63
30	Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 381-388.	1.5	12
31	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 439-451.	2.8	68